The Real World Study-Document Index (RWS-DI) is a framework developed by a working group of RWE experts to address the challenges of filing essential documents for non-interventional and observational studies. The RWS-DI is designed to be consistent with the TMF Reference Model (TMF RM) format and structure, but removes artifacts specific to clinical trials and replaces terminology to reflect the unique nature of real-world studies.
Key differences between the TMF Reference Model (TMF RM) and the Real World Study-Document Index (RWS-DI) are:
[1] TMF Reference Model:
– An industry-adopted reference structure for the TMF that takes the form of an index.
– Provides a model of a complete TMF, which can then be customized as needed for a specific clinical study.
– Assigns documents to a comprehensive taxonomy complete with standard nomenclature to enable consistent filing.
– Developed primarily from a sponsor perspective, which makes it difficult for sites to adopt due to its larger scope and non-intuitive terminology.
Link: https://lnkd.in/eV4cH4At
[2] Real World Study-Document Index:
– A framework developed by a working group of real-world study (RWS) experts to address the challenges of filing essential documents for non-interventional and observational studies.
– Based on a prospective study design to provide maximum coverage of the potential document or artifact types across the range of real-world study designs.
– Designed to be consistent with the TMF RM format and structure, but removes artifacts specific to clinical trials and replaces terminology such as “trial” with “study” and “subject” with “patient.”
– A stand-alone deliverable that is expected to evolve to reflect user community requirements.
Link1: https://lnkd.in/eNUnsKR6
Link2: https://lnkd.in/eU6vf8qN
Overall, it is important for organizations to understand the regulatory requirements for TMF management and determine which framework is best suited for their specific study design.
Share this story...
Real World Evidence (RWE) 101 – Parkinson’s Disease
RWE 101 - Parkinson’s Disease Real-world evidence (RWE) refers to clinical evidence regarding the usage and potential benefits or risks of a treatment derived from analysis of real-world data [...]
Real World Evidence (RWE) 101 – Benefits of RWE in the Context of Rare Diseases
RWE 101 - Benefits of RWE in the Context of Rare Diseases Real-world evidence (RWE) refers to information on health care that comes from real-world settings, such as electronic [...]
Real World Evidence (RWE) 101 – Disease Prevalence vs Incidence
RWE 101 - Disease Prevalence vs Incidence Real-world evidence (RWE), derived from real-world data (RWD), allows us to gain insights into disease prevalence and incidence outside of controlled clinical [...]
Real World Evidence (RWE) 101 – Principles for Ensuring that Research Results are Reliable, Valid, and Objective
RWE 101 - Principles for Ensuring that Research Results are Reliable, Valid, and Objective Ensuring that research results are reliable, valid, and objective requires careful planning, execution, and evaluation. [...]
Real World Evidence (RWE) 101 – Why Should Non-Interventional Studies NOT be Promotional?
RWE 101 - Why Should Non-Interventional Studies NOT be Promotional? Non-interventional studies (NIS) are designed to observe and analyze data from real-world clinical settings without intervening or manipulating any [...]
Real World Evidence (RWE) 101 – Seeding Studies
RWE 101 - Seeding Studies Seeding studies, in the context of real-world evidence (RWE), refer to studies that were conducted by pharmaceutical or medical device companies after a product's [...]







